Accentia Biopharmaceuticals, Inc. (NASDAQOTH:ABPI)

CAPS Rating: No stars

A biopharmaceutical company focused on the development & commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease &, through its publicly-traded subsidiary, Biovest International Inc., oncology.

Recs

1
Player Avatar gingerlade (< 20) Submitted: 12/28/2007 8:09:34 PM : Outperform Start Price: $3.14 ABPI Score: -138.37

The company has a few blockbuster biopharmaceuticals in the pipeline awaiting
fast track and FDA approval...SinuNase (BDSI)and
Revimmune for 80 autoimmune diseases focusing
for now on relapse-remit MS....and a vaccine
for Hodgkins Lymphoma and a Biovac machine
to administer this on fast track....the
vaccine is being put out by BVTI a subsidiary
of APBI....Great potential this stock....of
course this is my humble opinion....as always
one must do their own research into this...
but once you do...you will be flabbergasted
at the potential of these multi-billion
dollar blockbusters if they pass FDA approval...Awesome promise....

Featured Broker Partners


Advertisement